Established Investigators Academic-Industry Partnership Awards

0 Saves · 0 Shares · 0 Comments Discussion

Grant Name

Funder

Melanoma Research Alliance (MRA)

Country or Region

United States

Research Field

Biological Markers & Sensor Mechanisms

Cancer Biology

Cancer or Carcinogenesis

Cancer Prevention

Clinical Research or Studies

Clinical Trials

Immunotherapy

Medical Diagnosis

Medical Treatment

Oncology

Skin Cancer

Skin Diseases

Technology Assessment or Transfer (Medical)

Therapy Evaluation

Tumors

Deadline

November 4, 2021 (Expired)

Grant Size

Upper $375,000USD Up to $125,000 per year for three years (up to $375,000 total). Industry partner must provide funds and/or in-kind support (e.g., reagents, clinical grade drugs, equipment, and contract services) that matches or exceeds MRA funds for the award period. Non-contract industry personnel costs may not be counted as in-kind support.

Contact Info

Rachel Fischer, Ph.D., MRA Senior Associate, Scientific Program and Grants Administration rfischer@curemelanoma.org

Eligibility

- Applicants must be a senior investigator, past the initial four years of their first academic faculty appointment. - Applicants must hold a full-time faculty appointment at the level of Assistant Professor (or equivalent) or above. - Applicants must identify an industry partner at the time of application. - Industry scientists may serve as co-investigators or collaborators, but may not be PIs.

Description

The Academic-Industry Partnership Award (for Established Investigators) is designed to enhance translational research by extending academic capabilities to clinical investigations and to facilitate interactions between the academic and industrial research sectors. These awards will be cofunded by MRA and an industry partner whose involvement is essential to the project.For the 2020-2021 cycle, MRA seeks proposals in the following areas, which are focused on current unmet clinical needs in melanoma. These areas are of particular interest, will receive special consideration, and can include pre-clinical, translational, clinical, and/or correlative studies:
- Identifying strategies to overcome primary and secondary treatment resistance;
- Developing treatment strategies for difficult-to-treat melanoma subtypes such as acral, mucosal, or uveal melanoma, and/or non-BRAF mutant melanomas including NRAS and NF1 mutants;
- Uncovering novel mechanisms of melanoma initiation and progression in order to improve prevention and early detection strategies, develop early treatment approaches such as adjuvant and neoadjuvant therapies, and identify prognostic biomarkers of high-risk disease/precursor lesions; and
- Developing strategies to prevent and/or treat metastatic disease, including in transit and/or satellite metastases, and leptomeningeal disease. Eligibility - Applicants must be a senior investigator, past the initial four years of their first academic faculty appointment. - Applicants must hold a full-time faculty appointment at the level of Assistant Professor (or equivalent) or above. - Applicants must identify an industry partner at the time of application. - Industry scientists may serve as co-investigators or collaborators, but may not be PIs.

Website

http://www.curemelanoma.org/research/request-for-proposals/

Funding resources
Purdue Grant Writing Lab: Introduction to Grant Writing	Open Link
University of Wisconsin Writing Center: Planning and Writing a Grant Proposal	Open Link